Skip to content

Fast Facts

Company Overview

Allergan is a multi-specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life’s potential. Today, we have approximately 11,500 highly dedicated and talented employees, global marketing and sales capabilities with a presence in more than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals, biologics, medical devices and over-the-counter consumer products, and state-of-the-art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully. From our beginnings as an eye care company to our focus today on several medical specialties, including ophthalmology, neurosciences, medical aesthetics, medical dermatology, breast aesthetics and urologics, Allergan is proud to celebrate more than 60 years of medical advances and proud to support the patients and physicians who rely on our products and the employees and communities in which we live and work.

Number of Employees

Allergan employs approximately 11,500 people worldwide and operates world-class research and development facilities and state-of-the-art manufacturing plants. In addition to its discovery-to-development research programs, Allergan has global marketing and sales capabilities, with a presence in more than 100 countries.

Year Founded

1950

Corporate Headquarters

Irvine, California

Chairman of the Board and CEO

David E. I. Pyott

President

Douglas S. Ingram, Esq.

Executive Committee

David E. I. Pyott
Raymond H. Diradoorian
James M. Hindman
Julian S. Gangolli
Douglas S. Ingram, Esq.
Arnold A. Pinkston
Scott D. Sherman
Scott M. Whitcup, M.D.

Key Financials

For the quarter ended September 30, 2014:

  • Allergan reported $1,790.7 million total product net sales. Total product net sales increased 17.2 percent, or 17.6 percent on a constant currency basis, compared to total product net sales in the third quarter of 2013.
  • Total specialty pharmaceuticals net sales increased 14.3 percent, or 14.6 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the third quarter of 2013.
  • Total core medical devices net sales increased 30.4 percent, or 31.1 percent on a constant currency basis, compared to total core medical devices net sales in the third quarter of 2013.

For the quarter ended June 30, 2014:

  • Allergan reported $1,827.3 million total product net sales. Total product net sales increased 15.9 percent compared to total product net sales in the second quarter of 2013.
  • Total specialty pharmaceuticals net sales increased 13.2 percent, or 13.7 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the second quarter of 2013.
  • Total core medical devices net sales increased 25.8 percent, or 26.1 percent on a constant currency basis, compared to total core medical devices net sales in the second quarter of 2013.
  • Total specialty pharmaceuticals and core medical devices net sales, which exclude sales from the transition services agreements related to the sale of the obesity intervention business unit, increased 15.1 percent, or 15.5 percent on a constant currency basis, compared to total specialty pharmaceuticals and core medical devices net sales in the second quarter of 2013.

For the quarter ended March 31, 2014:

  • Allergan reported $1,619.1 million total product net sales. Total product net sales increased 13.0 percent compared to total product net sales in the first quarter of 2013.
  • Total specialty pharmaceuticals net sales increased 10.4 percent, or 12.0 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the first quarter of 2013.
  • Total core medical devices net sales increased 23.3 percent, or 25.2 percent on a constant currency basis, compared to total core medical devices net sales in the first quarter of 2013.
  • Total specialty pharmaceuticals and core medical devices net sales, which exclude sales from the transition services agreements related to the sale of the obesity intervention business unit, increased 12.2 percent, or 13.9 percent on a constant currency basis, compared to total specialty pharmaceuticals and core medical devices net sales in the first quarter of 2013.

For the quarter ended December 31, 2013:

  • Allergan reported $1,659.6 million total product net sales. Total product net sales increased 14.6 percent compared to total product net sales in the fourth quarter of 2012. On a constant currency basis, total product net sales increased 15.6 percent compared to total product net sales in the fourth quarter of 2012.
  • Total specialty pharmaceuticals net sales increased 14.0 percent, or 15.0 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the fourth quarter of 2012.
  • Total core medical devices net sales increased 17.0 percent, or 17.8 percent on a constant currency basis, compared to total core medical devices net sales in the fourth quarter of 2012.

For the quarter ended September 30, 2013:

  • Allergan reported $1,528.4 million total product net sales. Total product net sales increased 12.9 percent compared to total product net sales in the third quarter of 2012. On a constant currency basis, total product net sales increased 14.0 percent compared to total product net sales in the third quarter of 2012.
  • Total specialty pharmaceuticals net sales increased 12.8 percent, or 13.9 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the third quarter of 2012.
  • Total medical devices net sales increased 13.4 percent, or 14.6 percent on a constant currency basis, compared to total medical devices net sales in the third quarter of 2012.

For the quarter ended June 30, 2013:

  • Allergan reported $1,577.0 million total product net sales. Total product net sales increased 10.6 percent compared to total product net sales in the second quarter of 2012. On a constant currency basis, total product net sales increased 10.9 percent compared to total product net sales in the second quarter of 2012.
  • Total specialty pharmaceuticals net sales increased 11.1 percent, or 11.5 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the second quarter of 2012.
  • Total medical devices net sales increased 7.4 percent, or 7.7 percent on a constant currency basis, compared to total medical devices net sales in the second quarter of 2012.

For the quarter ended March 31, 2013:

  • Allergan reported $1,432.5 million total product net sales. Total product net sales increased 8.4 percent compared to total product net sales in the first quarter of 2012. On a constant currency basis, total product net sales increased 9.0 percent compared to total product net sales in the first quarter of 2012.
  • Total specialty pharmaceuticals net sales increased 8.1 percent, or 8.7 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the first quarter of 2012.
  • Total medical devices net sales increased 10.2 percent, or 10.5 percent on a constant currency basis, compared to total medical devices net sales in the first quarter of 2012.

For the quarter ended December 31, 2012:

  • Allergan reported $1,484.6 million total product net sales. Total product net sales increased 7.4 percent compared to total product net sales in the fourth quarter of 2011. On a constant currency basis, total product net sales increased 8.1 percent compared to total product net sales in the fourth quarter of 2011.
  • Total specialty pharmaceuticals net sales increased 8.2 percent, or 9.0 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the fourth quarter of 2011.
  • Total medical devices net sales increased 2.9 percent, or 3.6 percent on a constant currency basis, compared to total medical devices net sales in the fourth quarter of 2011.

For the quarter ended September 30, 2012:

  • Allergan reported $1,391.1 million total product net sales. Total product net sales increased 6.1 percent compared to total product net sales in the third quarter of 2011. On a constant currency basis, total product net sales increased 9.4 percent compared to total product net sales in the third quarter of 2011.
  • Total specialty pharmaceuticals net sales increased 8.1 percent, or 11.4 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the third quarter of 2011.
  • Total medical devices net sales decreased 4.0 percent, or 0.3 percent on a constant currency basis, compared to total medical devices net sales in the third quarter of 2011.

For the quarter ended June 30, 2012

  • Allergan reported $1,467.4 million total product net sales. Total product net sales increased 4.8 percent compared to total product net sales in the second quarter of 2011. On a constant currency basis, total product net sales increased 8.7 percent compared to total product net sales in the second quarter of 2011.
  • Total specialty pharmaceuticals net sales increased 5.0 percent, or 8.8 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the second quarter of 2011.
  • Total medical devices net sales increased 4.0 percent, or 8.3 percent on a constant currency basis, compared to total medical devices net sales in the second quarter of 2011.

For the quarter ended March 31, 2012

  • Allergan reported $1,365.7 million total product net sales. Total product net sales increased 9.0 percent compared to total product net sales in the first quarter of 2011. On a constant currency basis, total product net sales increased 10.4 percent compared to total product net sales in the first quarter of 2011.
  • Total specialty pharmaceuticals net sales increased 10.8 percent, or 12.2 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the first quarter of 2011.
  • Total medical devices net sales increased 0.8 percent, or 2.0 percent on a constant currency basis, compared to total medical devices net sales in the first quarter of 2011.

For the quarter ended December 31, 2011

  • Allergan reported $1,382.8 million total product net sales. Total product net sales increased 7.2 percent compared to total product net sales in the fourth quarter of 2010. On a constant currency basis, total product net sales increased 8.2 percent compared to total product net sales in the fourth quarter of 2010.
  • Total specialty pharmaceuticals net sales increased 8.9 percent, or 10.1 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the fourth quarter of 2010.
  • Total medical devices net sales increased 1.0 percent, or 0.4 percent on a constant currency basis, compared to total medical devices net sales in the fourth quarter of 2010.

For the quarter ended September 30, 2011

  • Allergan reported $1,311.1 million total product net sales. Total product net sales increased 10.0 percent compared to total product net sales in the third quarter of 2010. On a constant currency basis, total product net sales increased 7.2 percent compared to total product net sales in the third quarter of 2010.
  • Total specialty pharmaceuticals net sales increased 10.1 percent, or 7.5 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the third quarter of 2010.
  • Total medical devices net sales increased 9.2 percent, or 5.6 percent on a constant currency basis, compared to total medical devices net sales in the third quarter of 2010.

For the quarter ended June 30, 2011

  • Allergan reported $1,400.4 million total product net sales. Total product net sales increased 13.7 percent compared to total product net sales in the second quarter of 2010. On a constant currency basis, total product net sales increased 9.6 percent compared to total product net sales in the second quarter of 2010.
  • Total specialty pharmaceuticals net sales increased 14.0 percent, or 10.1 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the second quarter of 2010.
  • Total medical devices net sales increased 12.2 percent, or 7.0 percent on a constant currency basis, compared to total medical devices net sales in the second quarter of 2010.

For the quarter ended March 31, 2011

  • Allergan reported $1,252.8 million total product net sales. Total product net sales increased 13.3 percent compared to total product net sales in the first quarter of 2010. On a constant currency basis, total product net sales increased 12.2 percent compared to total product net sales in the first quarter of 2010.
  • Total specialty pharmaceuticals net sales increased 13.3 percent, or 12.3 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the first quarter of 2010.
  • Total medical devices net sales increased 13.0 percent, or 11.9 percent on a constant currency basis, compared to total medical devices net sales in the first quarter of 2010.

For the quarter ended December 31, 2010

  • Allergan reported $1,290.1 million total product net sales. Total product net sales increased 6.9 percent compared to total product net sales in the fourth quarter of 2009. On a constant currency basis, total product net sales increased 7.4 percent compared to total product net sales in the fourth quarter of 2009.
  • Total specialty pharmaceuticals net sales increased 6.9 percent, or 7.3 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the fourth quarter of 2009.
  • Total medical devices net sales increased 7.1 percent, or 7.9 percent on a constant currency basis, compared to total medical devices net sales in the fourth quarter of 2009.

For the quarter ended September 30, 2010

  • Allergan reported $1,192.0 million total product net sales. Total product net sales increased 5.7 percent compared to total product net sales in the third quarter of 2009. On a constant currency basis, total product net sales increased 6.3 percent compared to total product net sales in the third quarter of 2009.
  • Total specialty pharmaceuticals net sales increased 6.9 percent, or 7.3 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the fourth quarter of 2009.
  • Total medical devices net sales increased 7.1 percent, or 7.9 percent on a constant currency basis, compared to total medical devices net sales in the fourth quarter of 2009.

For the quarter ended June 30, 2010

  • Allergan reported $1,231.7 million total product net sales. Total product net sales increased 10.1 percent compared to total product net sales in the second quarter of 2009. On a constant currency basis, total product net sales increased 9.3 percent compared to total product net sales in the second quarter of 2009.
  • Total specialty pharmaceuticals net sales increased 10.0 percent, or 9.2 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the second quarter of 2009.
  • Total medical devices net sales increased 10.6 percent, or 10.0 percent on a constant currency basis, compared to total medical devices net sales in the second quarter of 2009.

For the quarter ended March 31, 2010

  • Allergan reported $1,105.8 million total product net sales. Total product net sales increased 11.2 percent compared to total product net sales in the first quarter of 2009. On a constant currency basis, total product net sales increased 6.9 percent compared to total product net sales in the first quarter of 2009.
  • Total specialty pharmaceuticals net sales increased 9.7 percent, or 5.6 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the first quarter of 2009.
  • Total medical devices net sales increased 18.4 percent, or 13.4 percent on a constant currency basis, compared to total medical devices net sales in the first quarter of 2009.

2009

  • For the year ending 2009, total product net sales totaled $4,447.6 million, a 2.5 percent increase over 2008.


  1. Adjustments to GAAP research and development expense used to calculate research and development expense, adjusted for non-GAAP items, include the following: $68.7 million for upfront payments for technologies, that have not achieved regulatory approval and $0.3 million of termination benefits related to the phased closure of the Arklow, Ireland, breast implant manufacturing plant in 2008; $72.0 million of in-process research and development expense related to the EndoArt acquisition in 2007; $579.3 million of in-process research and development expense related to the Inamed acquisition, $0.2 million of Inamed integration and transition costs and $0.5 million of transition/duplicate operating expenses in 2006; and $1.5 million of transition/duplicate operating expenses and a $3.0 million buy-out of a license agreement in 2005. GAAP research and development expense was $797.9 million, $718.1 million, $1,055.5 million, $388.3 million, and $342.9 million in 2008, 2007, 2006, 2005 and 2004, respectively. GAAP research and development expense growth (decline) was 11%, (32%), 172%, 13% and (55%) for 2008, 2007, 2006, 2005 and 2004, respectively.
  2. Internal analysis of public filing of Allergan peer group.